Description of the ICTI consortium: An integrated approach to the study of Chlamydia trachomatis infection

Drugs of Today

Volumn 42, Issue SUPPL. A, 2006, Pages 107-114

  Morré, Servaas A ^a   Spaargaren, J ^b   Ossewaarde, J M ^c   Land, J A ^d   Bax, C J ^e   Dorr P J ^e   Oostvogel, P M ^f   Vanrompay, D ^f   Savelkoul, P H M ^a   Pannekoek, Y ^g   Van Bergen, J E A M ^h   Fennema, H S A ^b   De Vries, H J ^b   Crusius, J B A ^a   Pena A S ^a   Ito, J I ⁱ   Lyons, J M ⁱ  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

^f GHENT UNIVERSITY   (Belgium)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h National Institute for STI and AIDS Control in the Netherlands   (Netherlands)

ⁱ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; GAMMA INTERFERON; TOLL LIKE RECEPTOR 4; VIRULENCE FACTOR;

BACTERIAL INFECTION; BACTERIAL TRANSMISSION; CHLAMYDIA TRACHOMATIS; CONFERENCE PAPER; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG TOLERANCE; ECTOPIC PREGNANCY; ENVIRONMENTAL FACTOR; HUMAN; INFERTILITY; NONHUMAN; PELVIC INFLAMMATORY DISEASE; SEROTYPE; SYMPTOM;

ANIMALS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DISEASE MODELS, ANIMAL; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MICE;

EID: 33645457645     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Workowski, K.A., Lampe, M.F., Wong, K.G., Watts, M.B., Stamm, W.E. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy: Evidence against persistent infection. JAMA 1993, 270: 2071-5.
2. Scholes, D., Stergachis, A., Heidrich, F.E., Andrilla, H., Holmes, K.K., Stamm, W.E. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996, 334: 1362-6.
3. van Valkengoed, I.G., Morré, S.A., van den Brule, A.J. et al. Follow-up, treatment, and reinfection rates among asymptomatic Chlamydia trachomatis cases in general practice. Br J Gen Pract 2002, 52(481): 623-7.
4. Gerbase, A.C., Rowley, J.T., Heymann, D.H., Berkley, S.F., Piot, P. Global prevalence and incidence estimates of selected curable STDs. Sex Trans Infect 1998, 74(Suppl 1): S12-16.
5. Miller, W.C., Ford, C.A., Morris, M. et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004, 291: 2229-36.
6. van Valkengoed, I.G.M., Morré, S.A., van den Brule, A.J.C., Meijer, C.J.L.M., Bouter, L.M., Boeke, A.J.P. Overestimation of complication-rates of Chlamydia trachomatis screening programmes: Implications for cost-effectiveness analyses. Int J Epidemiol 2004, 33:416-25.
7. Hillis, S.D., Owens, L.M., Marchbanks, P.A., Amsterdam, L.F., MacKenzie, W.R. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997, 176: 103-7.
8. van Valkengoed, I.G.M. Asymptomatic Chlamydia trachomatis infections: should we screen? Thesis, Vumc, Amsterdam, The Netherlands 2001.
9. Lin, J.S.L., Donegan, S.P., Heeren, T.C. et al. Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. J Infect Dis 1998, 178: 1707-12.
10. van Valkengoed, I.G., Morré, S.A., van den Brule, A.J. et al. Follow-up, treatment, and reinfection rates among asymptomatic chlamydia trachomatis cases in general practice. Br J Gen Pract 2002, 52(481): 623-7.
11. Zimmermann, H.L., Potterat, J.J., Dukes, R.L. et al. Epidemiologic differences between chlamydia and gonorrhea. Am J Public Health 1990, 80: 1338-42.
12. Stamm, W.E. Diagnosis of Chlamydia trachomatis genitourinary infections. Ann Intern Med 1988, 108: 710-7.
13. Morré, S.A., Rozendaal, L., van Valkengoed, I.G.M. et al. Urogenital Chlamydia trachomatis serovars in men and women having either a symptomatic or an asymptomatic infection: An association with clinical manifestations? J Clin Microbiol 2000, 38(6): 2292-6.
14. Morré, S.A. Chlamydia trachomatis infections in the human urogenital tract. Detection, typing and clinical aspects. Thesis, VUmc, Amsterdam, The Netherlands 1999.
15. Golden, M.R., Schillinger, J.A., Markowitz, L., St. Louis, M.E. Duration of untreated genital infections with Chlamydia trachomatis. A review of the literature. Sex Transm Dis 2000, 27: 329-37.
16. Morré, S.A., van den Brule, A.J., Rozendaal, L. et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002, 13 (Suppl 2): 12-8.
17. Golden, M.R., Whittington, W.L., Handsfield, H.H. et al. Effect of expedited treatment of sex panners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 17; 352(7): 676-85.
18. Weström, L., Joesoef, R., Reynolds, G., Hadgu, A., Thompson, S.E. Pelvic inflammatory disease and fertility. A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Trans Dis 1992, 19: 185-92.
19. Morré, S.A., Murillo, L.S., Bruggeman, C.A., Pena, A.S. The role that the functional Asp299Gly polymorphism in the Toll-like receptor-4 gene plays in susceptibility to Chlamydia trachomatis-associated tubal infertility. J Infect Dis 2003, 187(2): 341-2.
20. Morré, S.A., Weite, R., Postma, M.J. Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing. Sex Transm Infect 2002, 78(1): 74-5.
21. Morré, S.A., Lyons, J.M., Ito, J.I. Jr. Murine models of Chlamydia trachomatis genital tract infection: Use of mouse pneumonitis strain versus human strains. Infect Immun 2000, 68(12): 7209-11.
22. Lyons, J.M., Ito, J.I. Jr, Pena, A.S., Morré, S.A. Differences in growth characteristics and elementary body associated cytotoxicity between Chlamydia trachomatis oculogenital serovars D and H and Chlamydia muridarum. J Clin Pathol 2005, 58(4): 397-401.
23. Lyons, J.M., Ito, J.I. Jr. Reducing the risk of Chlamydia trachomatis genital tract infection by evaluating the prophylactic potential of vaginally applied chemicals. Clin Infect Dis 1995, 21 (Suppl 2): S174-7.
24. Ito, J.I. Jr, Lyons, J.M., Airo-Brown, L.P. Variation in virulence among oculogenital serovars of Chlamydia trachomatis in experimental genital tract infection. Infect Immun 1990, 58(6): 2021-3.
25. Bax, C.J., Dorr, P.J., Trimbos, J.B. et al. Chlamydia trachomatis heat shock protein 60 (cHSP60) antibodies in women without and with tubal pathology using a new commercially available assay. Sex Transm Infect 2004, 80(5): 415-6.
26. Bax, C.J., Mutsaers, J.A., Jansen, C.L., Trimbos, J.B., Dorr, P.J., Oostvogel, P.M. Comparison of serological assays for detection of Chlamydia trachomatis antibodies in different groups of obstetrical and gynecological patients. Clin Diagn Lab Immunol 2003, 10(1): 174-6.
27. Bax, C.J., Oostvogel, P.M., Mutsaers, J.A. et al. Clinical characteristics of Chlamydia trachomatis infections in a general outpatient department of obstetrics and gynaecology in the Netherlands. Sex Transm Infect 2002, 78(6): E6.
28. Vanrompay, D., Hoang, T.Q.T., De Vos, L. et al. Specific pathogen free pigs as an additional animal model for studying Chlamydia trachomatis genital infection. Infect Immun 2005 (in press).
29. Vanrompay, D., Cox, E., Volckaert, G., Goddeeris, B. Turkeys are protected from infection with Chlamydia psittaci by plasmid DNA vaccination against the major outer membrane protein. Clin Exp Immunol 1999, 118(1): 49-55.
30. Vanrompay, D., Charlier, G., Ducatelle, R., Haesebrouck, F. Ultrastructural changes in avian Chlamydia psittaci serovar A-, B-, and D-infected Buffalo green monkey cells. Infect Immun 1996, 64(4): 1265-71.
31. Morré, S.A., Ossewaarde, J.M., Savelkoul, P.H., Stoof, J., Meijer, C.J., van den Brule, A.J. Analysis of genetic heterogeneity in Chlamydia trachomatis clinical isolates of serovars D, E, and F by amplified fragment length polymorphism. J Clin Microbiol 2000, 38(9): 3463-6.
32. Meijer, A., Morré, S.A., van den Brule, A.J., Savelkoul, P.H., Ossewaarde, J.M. Genomic relatedness of Chlamydia isolates determined by amplified fragment length polymorphism analysis. J Bacteriol 1999, 181(15): 4469-75.
33. Peters, R.P., van Agtmael, M.A., Danner, S.A., Savelkoul, P.H., Vandenbroucke-Grauls, C.M. New developments in the diagnosis of bloodstream infections. Lancet Infect Dis 2004, 4(12): 751-60.
34. Nieuwenhuis, R.F., Ossewaarde, J.M., Götz, H.M. et al. Resurgence of lymphogranuloma venereum in Western Europe: An outbreak of Chlamydia trachomatis serovar 12 proctitis in The Netherlands among men who have sex with men. Clin Infect Dis 2004, 39(7): 996-1003.
35. Ossewaarde, J.M., Meijer, A. Molecular evidence for the existence of additional members of the order Chlamydiales. Microbiology 1999, 145 (Pt 2): 411-7.
36. van Duynhoven, Y.T., Ossewaarde, J.M., Derksen-Nawrocki, R.P., van der Meijden, W.I., van de Laar, M.J. Chlamydia trachomatis genotypes: Correlation with clinical manifestations of infection and patients' characteristics. Clin Infect Dis 1998, 26(2): 314-22.
37. Pannekoek, Y., Heurgue-Hamard, V., Langerak, A.A., Speijer, D., Buckingham, R.H., van der Ende, A. The N5-glutamine S-adenosyl-L-methionine- dependent methyltransferase PrmC/HemK in Chlamydia trachomatis methylates class 1 release factors. J Bacteriol 2005, 187(2): 507-11.
38. Pannekoek, Y., van der Ende, A., Eijk, P.P. et al. Normal IncA expression and fusogenicity of inclusions in Chlamydia trachomatis isolates with the incA I47T mutation. Infect Immun 2001, 69(7): 4654-6.
39. Pannekoek, Y., Spaargaren, J., Langerak, A., Merks, J., Morré, S.A., van der Ende, A. Interrelationship between polymorphism of incA, fusogenic properties of Chlamydia trachomatis strains. J Clin Microbiol 2005 (in press).
40. Spaargaren, J., Fennema, H.S.A., Morré, S.A., de Vries, H.J.C., Coutinho, R.A. A new LGV strain of Chlamydia trachomatis identified in men having sex with men in Amsterdam: An unrecognized outbreak 2002-2004. Emerg Infect Dis 2005 (in press).
41. Spaargaren, J., Verhaest, I., Mooij, S. et al. Analysis of Chlamydia trachomatis serovar distribution changes in the Netherlands (1986-2002). Sex Transm Infect 2004, 80(2): 151-2.
42. van de Laar, M.J., van Duynhoven, Y.T., Fennema, J.S. et al. Differences in clinical manifestations of genital chlamydial infections related to serovars. Genitourin Med 1996, 72(4): 261-5.
43. van Bergen, J., Götz, H.M., Richardus, J.H., Hoebe, C.J., Broer, J., Coenen, A.J. for the PILOT CT study group. Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: Results from the first national population based study in the Netherlands. Sex Transm Infect 2005, 81(1): 17-23.
44. van Bergen, J.E., Postma, M.J., Peerbooms, P.G., Spangenberg, A.C., Tjen-A-Tak, J., Bindels, P.J. Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Amsterdam using mailed home-collected urine samples. Int J STD AIDS 2004, 15(12): 797-802.
45. Van Bergen, J.E. Acceptability of home screening for chlamydial infection: Some remaining issues. Sex Transm Infect 2000, 76(4): 321-2.
46. Fiddelers, A.A., Land, J.A., Voss, G., Kessels, A.G., Severens, J.L. Cost-effectiveness of Chlamydia antibody tests in subfertile women. Hum Reprod 2005, 20(2): 425-32.
47. Land, J.A., Gijsen, A.P., Kessels, A.G., Slobbe, M.E., Bruggeman, C.A. Performance of five serological chlamydia antibody tests in subfertile women. Hum Reprod 2003, 18(12): 2621-7.
48. Land, J.A., Evers, J.L. Chlamydia infection and subfertility. Best Pract Res Clin Obstet Gynaecol 2002, 16(6): 901-12.